Pill Identifier App

Generic Depakote Availability

See also: Generic Depakote ER

Depakote is a brand name of divalproex sodium, approved by the FDA in the following formulation(s):

DEPAKOTE (divalproex sodium - capsule, delayed rel pellets; oral)

  • Manufacturer: ABBVIE
    Approval date: September 12, 1989
    Strength(s): EQ 125MG VALPROIC ACID [RLD] [AB]

DEPAKOTE (divalproex sodium - tablet, delayed release; oral)

  • Manufacturer: ABBVIE
    Approval date: March 10, 1983
    Strength(s): EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [RLD] [AB]
  • Manufacturer: ABBVIE
    Approval date: October 26, 1984
    Strength(s): EQ 125MG VALPROIC ACID [AB]

Has a generic version of Depakote been approved?

Yes. The following products are equivalent to Depakote:

divalproex sodium capsule, delayed rel pellets; oral

  • Manufacturer: DR REDDYS LABS LTD
    Approval date: January 23, 2009
    Strength(s): EQ 125MG VALPROIC ACID [AB]
  • Manufacturer: MYLAN
    Approval date: March 28, 2011
    Strength(s): EQ 125MG VALPROIC ACID [AB]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: January 27, 2009
    Strength(s): EQ 125MG VALPROIC ACID [AB]

divalproex sodium tablet, delayed release; oral

  • Manufacturer: ANCHEN PHARMS
    Approval date: November 3, 2008
    Strength(s): EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: April 21, 2011
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: July 29, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: LUPIN
    Approval date: July 29, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: MYLAN
    Approval date: July 29, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: MYLAN
    Approval date: March 17, 2009
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: NU PHARM
    Approval date: July 29, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: ORCHID HLTHCARE
    Approval date: November 25, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: SANDOZ
    Approval date: July 29, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: SUN PHARM INDS
    Approval date: July 29, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: TEVA
    Approval date: July 29, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: UNICHEM LABS LTD
    Approval date: April 5, 2011
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: UPSHER SMITH
    Approval date: July 29, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: VINTAGE
    Approval date: November 30, 2009
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: WATSON LABS FLORIDA
    Approval date: February 25, 2011
    Strength(s): EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: WOCKHARDT
    Approval date: July 31, 2008
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: March 5, 2009
    Strength(s): EQ 125MG VALPROIC ACID [AB], EQ 250MG VALPROIC ACID [AB], EQ 500MG VALPROIC ACID [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Depakote. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Depakote.

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Advertisement
Close

Recommended

(web2)